Molecular Partners AG Sponsored ADR (NASDAQ:MOLN) Short Interest Update

Molecular Partners AG Sponsored ADR (NASDAQ:MOLN) was the recipient of a large increase in short interest in May. As of May 29th, there was short interest totaling 10,189 shares, an increase of 67.9% from the May 14th total of 6,068 shares. Based on an average daily trading volume, of 7,808 shares, the days-to-cover ratio is currently 1.3 days. Currently, 0.0% of the shares of the stock are short sold.

Molecular Partners Stock Up 2.9%

Shares of NASDAQ:MOLN traded up $0.11 during midday trading on Tuesday, reaching $3.96. The company’s stock had a trading volume of 24,540 shares, compared to its average volume of 5,594. The firm has a market cap of $159.90 million, a price-to-earnings ratio of -2.04 and a beta of 1.07. Molecular Partners has a 1 year low of $3.41 and a 1 year high of $5.36. The business has a 50 day moving average price of $4.09 and a 200 day moving average price of $4.31.

Molecular Partners (NASDAQ:MOLN) last announced its quarterly earnings data on Monday, May 11th. The company reported ($0.45) EPS for the quarter, missing analysts’ consensus estimates of ($0.43) by ($0.02). Sell-side analysts anticipate that Molecular Partners will post -1.32 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of research firms recently issued reports on MOLN. HC Wainwright reaffirmed a “buy” rating and issued a $13.00 target price on shares of Molecular Partners in a research note on Wednesday, April 22nd. TD Cowen reaffirmed a “buy” rating on shares of Molecular Partners in a research note on Monday, March 16th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Molecular Partners in a research note on Friday, April 10th. Two investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock has a consensus rating of “Hold” and a consensus target price of $8.38.

Hedge Funds Weigh In On Molecular Partners

A hedge fund recently bought a new stake in Molecular Partners stock. SmartHarvest Portfolios LLC bought a new position in shares of Molecular Partners AG Sponsored ADR (NASDAQ:MOLN) in the fourth quarter, according to the company in its most recent filing with the SEC. The fund bought 12,311 shares of the company’s stock, valued at approximately $54,000. 26.55% of the stock is currently owned by institutional investors and hedge funds.

About Molecular Partners

Molecular Partners AG is a clinical-stage biopharmaceutical company headquartered in Zurich, Switzerland, specializing in the design and development of DARPin® (Designed Ankyrin Repeat Protein) therapies. These small, modular proteins are engineered to bind with high specificity and affinity to disease-relevant targets. The company’s technology platform aims to deliver novel treatments across multiple therapeutic areas by leveraging the unique properties of DARPins, including stability, tissue penetration and multi-specific binding capabilities.

The company’s development pipeline spans infectious diseases, ophthalmology and oncology.